Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drug Patent Challenge Notifications Will Be Announced By FDA

Executive Summary

FDA will soon begin posting announcements of ANDAs that have been filed with Paragraph IV certification on the Office of Generic Drugs web site.

You may also be interested in...



PhRMA Wants Amended ANDAs To Trigger 30-Month Stays

FDA should specify that ANDAs which change certification from Paragraph III to Paragraph IV should trigger for a 30-month stay, the Pharmaceutical Research & Manufacturers of America states in comments on FDA's proposed rule

PhRMA Wants Amended ANDAs To Trigger 30-Month Stays

FDA should specify that ANDAs which change certification from Paragraph III to Paragraph IV should trigger for a 30-month stay, the Pharmaceutical Research & Manufacturers of America states in comments on FDA's proposed rule

FDA Generic Drugs Office’s Scientific Advisory Team Will Direct Research

Studies of bioequivalence methods by FDA's Office of Generic Drugs will be directed by its Research Initiatives Committee

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel